Captopril: Determination in blood and pharmacokinetics after single oral dose

Jankowski, Andrzej; Skorek, A.; Krzyśko, Krystiana A.; Zarzycki, Paweł K.; Ochocka, Renata; Lamparczyk, H.

doi:10.1016/0731-7085(95)01319-g

Cited by 35 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparison dosages for the ACE inhibitors were determined by our board-certified cardiologist consultant and were set as the acute dose required for approximately equal changes in blood pressure in clinical applications based on previous studies (Lees & Reid, 1987;Agabiti-Rosei et al 1992;Jankowski et al 1995;Chik et al 2010). Furthermore, single dose studies in healthy human subjects have identified that plasma angiotensin II (Ang II) concentrations are reduced by 31% with both 25 mg captopril measured at 1 h post-ingestion (Hollenberg et al 1981) and 4 mg of perindopril measured at 4 h post-ingestion (Bussien et al 1986).…”

Section: Ace Inhibitorsmentioning

confidence: 99%

Effect of centrally acting angiotensin converting enzyme inhibitor on the exercise‐induced increases in muscle sympathetic nerve activity

Moralez

Jouett

Tian

et al. 2018

The Journal of Physiology

View full text Add to dashboard Cite

We tested the hypothesis that the signalling mechanisms associated with the dynamic exercise intensity related increases in muscle sympathetic nerve activity (MSNA) and arterial baroreflex resetting during exercise are located within the central nervous system. Participants performed three randomly ordered trials of 70° upright back-supported dynamic leg cycling after ingestion of placebo and two different lipid soluble angiotensin converting enzyme inhibitors (ACEi): perindopril (high lipid solubility), captopril (low lipid solubility). Repeated measurements of whole venous blood (n = 8), MSNA (n = 7) and arterial blood pressures (n = 14) were obtained at rest and during an acute (SS1) and prolonged (SS2) bout of steady state dynamic exercise. Arterial baroreflex function curves were modelled at rest and during exercise. Peripheral venous superoxide concentrations measured by electron spin resonance spectroscopy were elevated during exercise and were not altered by ACEi at rest (P ≥ 0.4) or during exercise (P ≥ 0.3). Baseline MSNA and mean arterial pressure were unchanged at rest (P ≥ 0.1; P ≥ 0.8, respectively). However, during both SS1 and SS2, the centrally acting ACEi perindopril attenuated MSNA compared to captopril and the placebo (P < 0.05). Arterial pressures at the operating point and threshold pressures were decreased with perindopril from baseline to SS1 with no further changes in the operating point pressure during SS2 under all three conditions. These data suggest that centrally acting ACEi is significantly more effective at attenuating the increase in the acute and prolonged exercise-induced increases in MSNA.

show abstract

Section: Ace Inhibitorsmentioning

confidence: 99%

Effect of centrally acting angiotensin converting enzyme inhibitor on the exercise‐induced increases in muscle sympathetic nerve activity

Moralez

Jouett

Tian

et al. 2018

The Journal of Physiology

View full text Add to dashboard Cite

show abstract

“…Jankowski et al. [] used p ‐bromophenacyl bromide ( p ‐BPB) both as stabilizing and chromophoric agent to determine CAP in pharmaceutical tablets using a mobile phase consisting of acetonitrile–1% acetic acid (60:40, v/v) in an isocratic mode. Bahmaei et al.…”

Section: Liquid Chromatographymentioning

confidence: 99%

Separation methods for captopril in pharmaceuticals and biological fluids

Mansour¹,

Danielson²

2012

J of Separation Science

View full text Add to dashboard Cite

Captopril (CAP) is an orally active angiotensin‐converting enzyme (ACE) inhibitor and has been widely used for management of hypertension and congestive heart failure. CAP lacks an aromatic chromophore required for facile direct UV detection and also has two chiral centers. These factors can render the determination of CAP in complex matrices challenging. This review covers more than 20 years of analytical research on this drug, focusing mainly on pharmaceutical and biological applications. The primary separation techniques discussed are gas chromatography, liquid chromatography, and capillary electrophoresis. The structures of the CAP derivatizing agents as well as a table summarizing various HPLC methods are provided. A discussion of key recent chromatographic and electrophoretic methods for other ACE inhibitors is also present.

show abstract

“…To assure the quality of CAP-containing pharmaceutical formulations, several methods have been reported for its determination, including fluorimetric methods (Imai, Toyoka, and Watanabi 1983;Cavrini et al 1988;Al-Ghannam, El-Brashy, and Al-Farhan 2002;Chen and Cai 2003), electrochemical methods (Mohamed, Aboul-Enein, and Gad-kariem 1983;Passamonti, Bartocci, and Pucciarelli 1987;Fraga et al 1998;Passamonti et al 1991;Pimenta, Araújo, and Montenegro 2001;Siangproh, Ngamukot, and Chailapakul 2003;Stefan, Hassan, and Aboul-Enein 2003), AAS (El Walily et al 1999;El Reis, Attia, and Kenawy 2000), chemiluminescence (Xinrong et al 1995;Zhang et al 1995Zhang et al , 1996Economou et al 2002), spectrophotometric methods (Shama, El-Sayed Amin, and Omara 2006;Basavaiah and Nagegowda 2004), capillary electrophoresis (Hillaert and Van den Bossche 1999), and chromatography (Matsuki et al 1980;Drummer, Jarrott, and Louis 1984;Ito et al 1987;Lin Ling et al 1989; Lin Baeyens 1990, 1991;Jankowski et al 1995;Liu et al 1995;Sypniewski and Bald 1996;Kok et al 1997;Ouyang et al 1999;Rao et al 2000;Mirza and Tan 2001). Flow-injection (FI) analysis is a well-established analytical technique that has advantages for routine analysis and quality-assurance control.…”

Section: Introductionmentioning

confidence: 99%

Flow-Injection Spectrophotometric Determination of Captopril Exploiting Silver Chloranilate Solid-Phase Reactor

et al. 2009

View full text Add to dashboard Cite

A novel, simple, and rapid flow-injection method for the spectrophotometric determination of captopril in pharmaceutical products, using a solid-phase reactor with silver chloranilate (Ag 2 C 6 Cl 2 O 4 ) immobilized in a polyester resin, is presented. This method explored the formation of an insoluble salt between Ag(I) and captopril in the solid-phase reactor, releasing chloranilate anion (C 6 Cl 2 O 2À 4 ). Then, this anion reacted with ferric ions to produce a complex, FeC 6 Cl 2 O þ 4 , which was monitored spectrophotometrically at 528 nm. The analytical curve was linear in the captopril concentration range from 1.0 Â 10 À5 to 5.0 Â 10 À4 mol l À1 with a detection limit of 8.0 Â 10 À6 mol l À1 . The relative standard deviation (RSD) was 0.35% (n ¼ 10) for a solution of 3.0 Â 10 À4 mol l À1 captopril solution, and an analytical frequency of 70 h À1 was obtained. The effects of excipients frequently found with captopril in pharmaceutical formulations, such as lactose, microcrystalline cellulose, starch, and magnesium stearate, were evaluated using the proposed flow-injection method. None of these substances caused significative interference 973 in the proposed method. The method was successfully applied to the determination of captopril in pharmaceutical products, and the results were compared with results obtained using a potentiometric method.

show abstract

Captopril: Determination in blood and pharmacokinetics after single oral dose

Cited by 35 publications

References 19 publications

Effect of centrally acting angiotensin converting enzyme inhibitor on the exercise‐induced increases in muscle sympathetic nerve activity

Effect of centrally acting angiotensin converting enzyme inhibitor on the exercise‐induced increases in muscle sympathetic nerve activity

Separation methods for captopril in pharmaceuticals and biological fluids

Flow-Injection Spectrophotometric Determination of Captopril Exploiting Silver Chloranilate Solid-Phase Reactor

Contact Info

Product

Resources

About